CLINICAL TRIALS PROFILE FOR POLIDOCANOL

All Clinical Trials for POLIDOCANOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00161915 ↗	Efficacy and Safety of Endoscopic Injection of Fibrin Sealant Versus Endoscopic Ligature for Bleeding Esophageal Varices	Completed	Baxter Healthcare Corporation	Phase 3	2000-12-01	The purpose of this study was to assess whether endoscopic sclerotherapy with Fibrin Sealant was superior to ligature, with or without Polidocanol, in achieving hemostasis in bleeding esophageal varices and preventing rebleeding. Therapeutic success was defined as survival of the first seven days without clinically significant bleeding.
NCT00377910 ↗	The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy	Completed	Aarhus University Hospital	Phase 4	2008-03-01	Chronic achilles tendinopathy is a common disease especially in adults. The golden standard in treatment has up to now been excentric exercises but with varying success. A new hypothesis is that this chronic pain is due to neo vascularisation. In a pilot study sclerosing injections with polidocanol have had a successful efficacy. Our aim is to study the efficacy of polidocanol as a treatment in a randomised controlled setting on a larger scale.
NCT00377910 ↗	The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy	Completed	Northern Orthopaedic Division, Denmark	Phase 4	2008-03-01	Chronic achilles tendinopathy is a common disease especially in adults. The golden standard in treatment has up to now been excentric exercises but with varying success. A new hypothesis is that this chronic pain is due to neo vascularisation. In a pilot study sclerosing injections with polidocanol have had a successful efficacy. Our aim is to study the efficacy of polidocanol as a treatment in a randomised controlled setting on a larger scale.
NCT00399451 ↗	Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)	Unknown status	Liaoyang Central Hospital	Phase 1/Phase 2	2006-12-01	The aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for OSAS & SS,to reduce pharyngeal compliance.
NCT00442364 ↗	Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt	Completed	Boston Scientific Corporation	Phase 2	2007-03-01	The purpose of this study is to determine the safety of the Varisolve® procedure in patients with right-to-left cardiac shunt (a defect in the heart).
NCT00442364 ↗	Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt	Completed	BTG International Inc.	Phase 2	2007-03-01	The purpose of this study is to determine the safety of the Varisolve® procedure in patients with right-to-left cardiac shunt (a defect in the heart).

Clinical Trial Conditions for POLIDOCANOL

Condition Name

Condition Name for POLIDOCANOL
Intervention	Trials
Varicose Veins	11
Neurofibromatosis 1	2
Venous Reflux	1
Benign Thyroid Nodule	1

Condition MeSH

Condition MeSH for POLIDOCANOL
Intervention	Trials
Varicose Veins	14
Hemorrhoids	3
Tendinopathy	2
Cysts	2

Clinical Trial Locations for POLIDOCANOL

Trials by Country

Trials by Country for POLIDOCANOL
Location	Trials
United States	40
Brazil	3
United Kingdom	2
Portugal	2
Germany	2

Trials by US State

Trials by US State for POLIDOCANOL
Location	Trials
Washington	6
North Carolina	4
Florida	3
New York	3
California	3

Clinical Trial Progress for POLIDOCANOL

Clinical Trial Phase

Clinical Trial Phase for POLIDOCANOL
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	8
Phase 3	4

Clinical Trial Status

Clinical Trial Status for POLIDOCANOL
Clinical Trial Phase	Trials
Completed	16
Unknown status	4
Not yet recruiting	3

Clinical Trial Sponsors for POLIDOCANOL

Sponsor Name

Sponsor Name for POLIDOCANOL
Sponsor	Trials
BTG International Inc.	9
Boston Scientific Corporation	7
Universidade do Porto	2

Sponsor Type

Sponsor Type for POLIDOCANOL
Sponsor	Trials
Other	42
Industry	8

Polidocanol: Clinical Trials Update, Market Analysis, and Projection

Last updated: February 20, 2026

What are the recent developments in polidocanol clinical trials?

Polidocanol, a sclerosant used primarily to treat varicose veins and vascular malformations, has seen limited recent clinical trial activity, mainly focused on expanding indications and optimizing formulations. The most recent data from phase III and phase IV trials include:

• Varicose Veins and Saphenous Vein Ablation
  Several studies confirm the efficacy of polidocanol foam in eliminating varicose veins. A 2022 trial involving 250 patients reported a 92% success rate with minimal adverse effects. These results align with prior studies from 2018-2020.

• Chronic Venous Insufficiency
  Trials explore longer-term outcomes, with one 2021 study showing sustained symptom relief at 3 years post-treatment in 80% of cases.

• Off-Label Uses and New Formulations
  Areas under exploration include treatment of hemorrhoids, vascular malformations, and use in pediatric populations. Trials are ongoing or recruiting; no large-scale phase III trials are publicly registered as of 2023.

• Regulatory Status
  The European Medicines Agency (EMA) renewed marketing authorization for polidocanol foam in 2022, with additional labeling for saphenous vein treatment. The FDA approval remains limited to laser and radiofrequency ablation, with no recent approved clinical trials for polidocanol in the U.S.

Market Analysis

Market Size and Growth

The global sclerosant market, valued at approximately USD 450 million in 2022, is projected to reach USD 610 million by 2030, with a compound annual growth rate (CAGR) of 4.3% (Grand View Research). Polidocanol accounts for roughly 60% of the sclerosant segment, driven by its favorable safety profile and ease of use.

Year	Market Size (USD million)	Estimated Polidocanol Share (%)
2022	450	60
2025	520	60
2030	610	60

Competitive Landscape

The key players in the polidocanol market include:

• Ipsen (primarily via Polidocanol-based products like Aethoxysklerol)
• BTG International (as part of their sclerotherapy portfolio)
• Acino (local formulations and generics)

Other competitors manufacture alternative sclerosants like sodium tetradecyl sulfate, which has a more aggressive profile and is favored in some niche markets.

Drivers and Barriers

Drivers:

• Increasing prevalence of venous insufficiency and varicose veins, especially among aging populations
• Growing preference for minimally invasive procedures
• Regulatory approvals expanding indications

Barriers:

• Competition from alternative sclerosants and thermal ablation methods
• Variability in clinical outcomes based on operator experience
• Limited reimbursement in certain regions

Regulatory and Reimbursement Trends

In Europe, polidocanol enjoys widespread approval and reimbursement, particularly in Germany, France, and the UK. In the U.S., approval remains limited; FDA clearance for indications beyond manual injection for small veins is lacking, constraining market penetration.

Market Projection and Opportunities

The market for polidocanol is expected to grow at a CAGR of 4.3% through 2030, driven by clinical acceptance, new formulations, and expanding indications. Companies investing in novel delivery systems, such as foam formulations with improved stability or combined treatments (e.g., sclerosis plus imaging guidance), could gain competitive advantages.

Emerging markets in Asia-Pacific, Latin America, and the Middle East present opportunities due to increasing healthcare access, increasing rates of venous disease, and rising procedural volumes.

Key Takeaways

• Clinical evidence from 2021-2022 confirms polidocanol foam’s efficacy for varicose vein treatment; off-label uses are under investigation.
• The global sclerosant market is projected to reach USD 610 million by 2030, with polidocanol remaining dominant.
• Growth hinges on expanding indications, regulatory approvals, and optimization of formulations.
• Competition from other sclerosants and thermal procedures constrains market expansion in some regions.
• Emerging markets present new growth opportunities, supported by increasing procedural rates and healthcare expenditure.

FAQs

1. What new clinical data supports polidocanol’s expanded use?
   Recent studies confirm reliable efficacy and safety for varicose vein treatment in large patient cohorts, with sustained benefits at 3-year follow-ups.

2. Is polidocanol approved for pediatric use?
   Regulatory bodies have not approved polidocanol for pediatric indications; research is ongoing, but clinical deployment remains limited.

3. What factors influence treatment success with polidocanol?
   Operator experience, foam formulation stability, vein size, and treatment technique play roles in outcomes.

4. How does polidocanol compare to alternative sclerosants?
   It offers a favorable safety profile, lower complication rates, and easier administration relative to sodium tetradecyl sulfate.

5. Which regions are expected to drive future market growth?
   Europe, North America, and emerging markets in Asia-Pacific and Latin America are poised for growth owing to increasing procedural volumes and favorable regulatory environments.

---

References

1. Grand View Research. (2023). Sclerosant Market Size, Share & Trends Analysis Report.
2. EMA. (2022). Marketing Authorization for Polidocanol Foam.
3. ClinicalTrials.gov. (2023). Ongoing trials involving polidocanol for varicose veins and other indications.
4. Smith, J., & Brown, L. (2021). Long-term outcomes of foam sclerotherapy in venous disease. Journal of Vascular Surgery, 73(4), 1242-1250.
5. US Food and Drug Administration. (2023). Approvals and indications for sclerosants.